Key Takeaways
- Margin recovery underway, but uneven: EBITDA margin improved 620 bps YoY to 12.9%, driven by easing input costs and NLEM price hikes in pharma, while the chemical segment limped at a 1.5% EBIT margin on acetic acid volatility.
- Paracetamol price collapse masked volume health: Capacity utilization ran at 90–95%, yet prices eroded over 80%, with an average ~25% YoY decline that materially compressed the top line.
- Non-ibuprofen API is the growth bet: Management targets ₹500–550 crore revenue for FY24 and 20–25% growth for the next 2–3 years, with European approvals starting to convert into sample orders.
- Chemical segment is a margin drag with a seasonal tailwind: EBIT margin at 1.5% reflects acetic acid volatility and internal API transfers at cost; Q3 and Q4 are historically better, so improvement is expected.
- What to watch next quarter: Whether paracetamol prices begin the promised recovery, the pace of non-ibuprofen export order conversion from European approvals, and any concrete update on the paracetamol expansion plan.
Margin Walk: Pharma Heals, Chemicals Bleeds
- Pharma segment delivered: EBIT margin reached 15% in Q2 FY24, helped by easing input costs and the 12.1% NLEM price hike benefit that kicked in from April 2023.
- Chemical segment stuck in single digits: EBIT margin was only 1.5%, with management stating the normalized longer-term range is "single digit... not more than that," historically 6–8%.
- Acetic acid was the culprit: Ethyl acetate raw material prices were very volatile, especially in September, while finished product prices remained flat, compressing the chemical bottom line.
- Other expenses spiked on operational factors: Rose to ~₹79 crore due to the start of acetic anhydride operations consuming more power, steam and gas, a boiler shutdown forcing higher-cost external power purchases, and seasonal Q2 utility effects.
- Internal transfer masked chemical performance: ~₹80 crore of chemical output shifted to API at cost price, understating the segment's standalone contribution.
- Power costs expected to ease: Management expects power and fuel expenses to decrease slightly in the coming quarter, which will reduce other expenses.
Mahajan: "It is single digit. I think not more than that."
Paracetamol: The Volume-Price Disconnect
- Volumes are strong, prices are not: Capacity utilization is high at 90–95% and volume growth is present, but prices have eroded by more than 80%, with an average ~25% YoY decline that significantly impacted the top line.
- Recovery expected, but back-end loaded: Management expects paracetamol prices to improve to some extent, which will increase the bottom line, but most recovery will come in Q4 FY24, with Q3 expected to be similar to Q2.
- Expansion plans under consideration: When asked about paracetamol expansion, management said they are "considering various avenues" and will come back next quarter with an update, offering no commitment.
- Regulatory credentials in place: A CEP for paracetamol was received during the first quarter, supporting export market access.
Mahajan: "The prices were drastically down during June and September quarter."
Non-Ibuprofen API: The Diversification Engine
- Revenue target of ₹500–550 crore for FY24: Management is "very hopeful" of crossing the ₹500 crore mark, with 20–25% growth expected for the next 2–3 financial years.
- European approvals converting to orders: Approvals have been received from various European authorities, sample orders are floating, and various customers have shown interest. Management expects increasing volume but says it will take 1–2 more quarters to ramp quantity.
- Export focus over domestic: Non-ibuprofen products will be sold more in the export market rather than domestically, with better net sales realization expected from regulated markets.
- Product pipeline building: 3–4 products have good filings in regulated markets, with paracetamol and metformin already doing well. Exports to regulated markets will increase EBITDA contribution.
- Metformin DMF approved without USFDA inspection: Available for all manufacturers who wish to buy, removing a regulatory hurdle.
- Sitagliptin process recognized but not yet commercial: Developed a clean, greener process that was a finalist among the top five out of 213 companies at CPHI Barcelona. No final decision on commercialization, pending market and economic viability assessment.
Singh: "Surely we are very hopeful about meeting our targets of around Rs 500 to 550 crore non-ibu business in this financial year."
Ibuprofen: Steady but Geographically Skewed
- Pricing stable quarter-on-quarter: Ibuprofen prices remained at the same level as the June and September quarters, with no substantial change.
- Revenues expected to sustain in H2: Management expects ibuprofen revenues to hold through the second half.
- US market share remains low: Management cited better net sales realization from Europe and Latin America regulated markets as the reason, stating there is "no constraint" to increasing US share, and that they are exploring opportunities to grow it.
- No capacity expansion planned: Running at ~90% capacity, management has no current plans to expand but says they are ready to do so within 3–6 months with backward integration if an opportunity arises.
Chemical Segment: New Capacity, Old Headwinds
- Acetic anhydride commercialized: The facility was completed in the June quarter and sales have started, with ~40% of present production sold domestically as the company enters a new segment and builds new customer relationships.
- Sales shown in chemical segment, but no uplift: Overall segment-level revenue remained flat due to a reduction in ethyl acetate prices offsetting the new acetic anhydride contribution.
- Seasonal pattern favors H2: Management noted that Q3 and Q4 are historically better for the chemicals vertical, and improvement is expected.
- Q2 is structurally the weakest quarter: Management acknowledged that every financial year, Q2 remains on the lower side and Q4 on the higher side for the business.
Singh: "I can say in that respect, every financial year, Q2 remains on the lower side and the Q4 remains on the higher side."
Capital Allocation & Balance Sheet
- CAPEX of ~₹200 crore this year: A similar pattern is expected for the next 2–3 years, majorly growth CAPEX. The proportionate split between chemical and API depends on market conditions and products finalized, and management says it is "pretty early to say" how much will go to each segment.
- No debt plans: CAPEX will be funded entirely through internal accruals, with cash generation from businesses exceeding investment needs.
- R&D budget under review: Management is working on increasing it and will make an appropriate announcement at an appropriate time, offering no specific commitment.
- Infrastructure additions: Recently added additional infrastructure including boilers, with a focus on green chemistry and environmental activities.
Mahajan: "Definitely. We have the projections and the estimates relating to the CAPEX's, the cash generations from the businesses is more than what we are looking to invest into the CAPEX."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | ~10% every year | FY24 and FY25 |
| EBITDA margin | 15% to 17% | FY24 and FY25 |
| Non-ibuprofen API revenue | ₹500 to ₹550 crore | FY24 |
| Non-ibuprofen API growth rate | 20% to 25% | Next 2–3 financial years |
| Quarterly recovery path | Q3 similar to Q2; most recovery in Q4 | FY24 |
| Ibuprofen revenues | Sustain at current levels | H2 FY24 |
| Power/fuel expenses | Decrease slightly | Coming quarter |
| Overall margins | Definite improvement | Next six months |
| CAPEX run-rate | ~₹200 crore per year | FY24 and next 2–3 years |
| Paracetamol expansion update | Management to provide details | Next quarter |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Total income | ₹552 cr, vs ₹546 cr in Q2 FY23 and ₹570 cr in Q1 FY24 |
| EBITDA | ₹71 cr, vs ₹37 cr in Q2 FY23 and ₹80 cr in Q1 FY24 |
| EBITDA margin | 12.9%, improved 620 bps YoY from 6.7%; 14% in Q1 FY24 |
| Net profit | ₹38 cr, vs ₹16 cr in Q2 FY23 and ₹46 cr in Q1 FY24 |
| EBIT margin – pharmaceutical segment | 15% |
| EBIT margin – specialty chemical segment | 1.5% |
| Revenue growth guidance | ~10% every year for FY24 and FY25 |
| EBITDA margin guidance | 15% to 17% for FY24 and FY25 |
| CAPEX incurred H1 FY24 | ₹114 cr, vs ₹211 cr for full FY23; full-year plan ~₹200 cr |
| Ibuprofen capacity utilization | ~90% |
| Paracetamol capacity utilization | 90%–95%, capacity recently increased from 1,800 to 3,600 |
| Non-ibuprofen API growth guidance | 20% to 25% for next 2–3 financial years |
| Other API revenue guidance FY24 | ₹500 to ₹550 cr, H1 at ~₹236 cr |
| Global market share – ibuprofen | 35% |
| Cash and equivalents | >₹250 cr, company totally debt free, no debt raised since 2017 |